Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. - Wikidata - awgldk - TriplyDB

Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

http://www.wikidata.org/entity/Q35673668

about

Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes Expanding the clinical indications for α(1)-antitrypsin therapy Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives Rapid renal alpha-1 antitrypsin gene induction in experimental and clinical acute kidney injury Context-Specific and Immune Cell-Dependent Antitumor Activities of α1-Antitrypsin α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.The immunoregulation effect of alpha 1-antitrypsin prolong β-cell survival after transplantation Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation.Modified extracorporeal photopheresis with cells from a healthy donor for acute graft-versus-host disease in a mouse model Advances in understanding the pathogenesis of graft-versus-host disease.RNA-Seq Analysis Reveals Genes Underlying Different Disease Responses to Porcine Circovirus Type 2 in Pigs.Alpha 1 Antitrypsin Inhibits Dendritic Cell Activation and Attenuates Nephritis in a Mouse Model of Lupus.Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation Effect of recombinant α1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes.α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.Exploration of α1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration.Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.Immune-modulating effects of alpha-1 antitrypsin.Next generation treatment of acute graft-versus-host disease.Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update.Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis.Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015).α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide-induced IL-1β in human blood neutrophils Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation.Embryonic Stem Cell Culture Conditions Support Distinct States Associated with Different Developmental Stages and Potency.α1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation.Human α1-Antitrypsin Binds to Heat-Shock Protein gp96 and Protects from Endogenous gp96-Mediated Injury In vivo Unique CD8+ T Cell-Mediated Immune Responses Primed in the Liver.Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis.Aged interleukin-10tm1Cgn chronically inflamed mice have substantially reduced fat mass, metabolic rate, and adipokines.Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.New and emerging therapies for acute and chronic graft versus host disease.Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.α1-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease.Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments.Novel therapeutic uses of alpha-1 antitrypsin: a window to the future.Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment.

P2860

Q26858837-AB688DCB-8106-4246-91D0-862FD8FE0AC1 Q26861561-FF1F9EB3-2BAA-4178-9F05-AF641A006662 Q27000764-F122BB0F-A353-4A15-A07E-8E068F30AB47 Q28075204-C06DBF5E-9BCF-4CBF-9455-9932BFEB09D7 Q28539030-3813B74A-84FC-421C-8110-3C97879773A4 Q28817846-639D9BA2-0FAA-4C5C-97FB-519EFFF66C64 Q34431458-4DB969A0-7861-4CD0-81BD-CE4B78013D3B Q35022269-ECEE6CC3-DF15-4DA4-8C5A-A7A4E5DEA079 Q35145461-B943A623-68C7-455B-8AA8-A8802BC1332A Q35179622-CEB8F5B5-B06E-4EE5-B9D5-B0FC063E4ACA Q35229872-77A4AFB2-F42C-432B-B5B9-4BFA89C02A0F Q35971439-57B71756-F9FD-479E-91B8-2ED3BCA47D31 Q36015404-55D27D92-BF97-47B8-AB32-A5A5006039E0 Q36032325-611DC101-A8A3-4A72-8141-4FE1FA3F9DE2 Q36305350-FD596FB0-988D-4017-AADE-BA615434F445 Q36885672-C87D7682-F2C6-4AEF-BC3D-83D2AD36B2DA Q37056456-D1DF491E-225C-4FAC-A9BF-E8C5B0A67AA4 Q37173117-94E5C618-E9D7-42AC-93DF-2409F61C36C8 Q37427900-2DD18D55-5338-4611-A32F-9C54BAE75A82 Q38132090-D5F65843-B0C2-46C8-9DAA-2D325C867432 Q38214040-4E2D3162-6D54-4C36-BA8A-742E6D84576E Q38221028-BB0581CA-6E26-44D4-A173-A15414D5EDC0 Q38643507-9A8AFCDB-79D9-45AD-B247-F2129C77B4CF Q38743931-A73E8324-7934-44DE-8DFC-57322105FD92 Q38769762-C340C965-890A-442B-8E38-0D99BBB1D02D Q39565971-DADB32C4-730C-46B7-A616-CF137E77B7F5 Q41642043-18F45ADD-8646-4F5E-AA4F-5959E8A137D2 Q41819037-B66CEA18-845B-4291-B14E-ADF591DF84BF Q42130122-2326AEDE-C74D-4C29-845C-4A368209AF3B Q42152837-AF43E0D1-D4F3-482B-B9FE-A3EBEE0E12F5 Q42429630-990F5D13-C715-4A92-9998-62CD586B7A2B Q43162026-970BE88D-FE0C-4EDC-B160-856D75C06605 Q47561544-CAAD37AB-D0FE-4BB6-B2C4-F414F1A031BE Q48141433-FAB9C38E-2E7B-4CCD-AEBD-A38C2F500044 Q49238507-C630DBA2-6BE8-4A64-B4E6-A0854938A398 Q49679320-3243477F-AC44-46FD-91AD-DB2C1949E588 Q50044411-FF101A03-A116-4505-BAD0-28A3E26CC723 Q51465416-1895A493-EFA8-4C20-B98E-5A18DB54AF77 Q51534901-75F52A6E-1595-4C96-867B-F4E00C6CC09B Q51568269-CD4192CD-22B9-42E2-B5C7-93BECCF3331C

P2860

Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

http://www.wikidata.org/entity/Q35673668

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@ast

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@en

type

label

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@ast

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@en

prefLabel

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@ast

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@en

P1433

Q35673668-1D216A5A-7248-4B78-B35C-2BFD919671E7

P1476

Q35673668-5B4B197F-8372-4878-80DA-01C7AF6F839B

P2093

Q35673668-1A2BC865-1BEA-40CA-B3F5-02765917EE27

Q35673668-282BC01B-5600-47B2-B147-66541CE6C405

Q35673668-4886672F-69EA-4B60-8985-1B9B21EC10E4

Q35673668-9DD43960-C7B8-4C69-A8C2-871F6542C244

Q35673668-B48E49F0-E497-439C-8D99-CBE3511C47DA

Q35673668-B8031CBF-A101-445F-A6B8-2E761AD40A6A

Q35673668-BFD03C5C-3F3B-4E71-8817-65CDCD4CA92E

Q35673668-D1B4A4DF-96E6-445B-B1D5-4246ACA468CE

P2860

Q35673668-00DE9201-A513-4EF2-9165-F42760BC298F

Q35673668-021218F7-3D6D-41DE-AAE8-61D88DE26E5B

Q35673668-0801C0BB-D08F-436A-8D91-4ED1E3219D53

Q35673668-13773B64-9043-4FF4-AAEA-F9900F954541

Q35673668-1BFAA28A-3E16-41D3-AB9C-566BBB81090E

Q35673668-1F9395D1-BF1E-48D2-836A-E99B52209C5D

Q35673668-2E18A57D-F4A7-4C5D-B0A4-E1D2DB00E15F

Q35673668-32FD5224-BD00-4A1C-B6AF-902E40417013

Q35673668-3F06FF53-F6FA-4736-B7D4-231CA15A59A7

Q35673668-47ED8FE8-7B29-4C09-9CB7-143C83C7074A

P304

Q35673668-2CA8514D-C588-4625-9BA7-887D32779F64

P31

Q35673668-B5F550D7-8CA5-48B1-B3EC-CA20612CC804

P356

Q35673668-93550EBC-4BD7-458C-9249-C6BB45BCAC2E

P407

Q35673668-4A977407-84E3-42B7-8646-B3EB3B120EE2

P433

Q35673668-674649F0-E967-44D2-879A-364F4B7C9C32

P478

Q35673668-417AF77B-F428-45B7-A7C2-4DBA63CACA39

P50

Q35673668-E44994EC-A399-431C-89AE-BF6534F878DE

P577

Q35673668-FF8F4A54-1878-475A-9BB2-B0E18E0FC9FF

P5875

Q35673668-91C890B9-9300-4239-B5A8-6A538387EC22

P698

Q35673668-D8D00777-A109-4E04-87BA-1FC4F9D6DBAA

P921

Q35673668-AF8661F5-9218-43F7-923C-E855820391B2

P932

Q35673668-0A68B0C1-5529-41D2-A2F8-48E81744DA17

P356

PNAS.1117665109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Alpha-1-antitrypsin monotherap ...... c bone marrow transplantation.

@en

P2093

Eli C Lewis

http://www.w3.org/2001/XMLSchema#string

Evelyn Nieves

http://www.w3.org/2001/XMLSchema#string

Isao Tawara

http://www.w3.org/2001/XMLSchema#string

Pavan Reddy

http://www.w3.org/2001/XMLSchema#string

Rebecca Evers

http://www.w3.org/2001/XMLSchema#string

Tania Azam

http://www.w3.org/2001/XMLSchema#string

Tomomi Toubai

http://www.w3.org/2001/XMLSchema#string

Yaping Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Human T regulatory cell therapy: take a billion or so and call me in the morning

Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis

Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1.

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Natural adjuvants: endogenous activators of dendritic cells.

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

Saving islets from allograft rejection.

P304

564-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1117665109

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Charles A. Dinarello

P577

2011-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51954349

http://www.w3.org/2001/XMLSchema#string

P698

22203983

http://www.w3.org/2001/XMLSchema#string

P921

P932

3258603

http://www.w3.org/2001/XMLSchema#string